Chronic Hand Eczema Market Expected to rise, 2034 | LEO Pharma, Japan Tobacco, Asana Biosciences, expected to drive market

The Chronic Hand Eczema market growth is driven by factors like increase in the prevalence of Chronic Hand Eczema, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Hand Eczema market report [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Hand Eczema market size, share, Chronic Hand Eczema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Hand Eczema market size growth forward.

Recent Breakthroughs in the Chronic Hand Eczema Market:

*
In September, 2024, LEO Pharma Inc. made two important announcements. First, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%) as a treatment for adults with moderate to severe Chronic Hand Eczema (CHE), particularly for those who have not responded to or cannot use topical corticosteroids.

*
In September 2024, LEO Pharma A/S announced that the European Commission (EC) granted marketing authorization for Anzupgo Registered (delgocitinib) cream. This approval provides a new treatment option for adult patients with moderate to severe CHE in Europe, particularly where traditional corticosteroid treatments have proven ineffective. These announcements underscore LEO Pharma's continued leadership in dermatological care and represent a significant step forward in improving treatment options for chronic hand eczema patients.

Some of the key highlights from the Chronic Hand Eczema Market Insights Report:

*
Several key pharmaceutical companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, and others, are developing novel products to improve the Chronic Hand Eczema treatment outlook.

*
According to DelveInsight, the chronic hand eczema market is expected to undergo significant changes during the forecast period (2024-2034), driven by advancements in medical research and technology, better diagnostic tools, and the introduction of new therapies.

*
In 2023, the total market size for chronic hand eczema in the United States was approximately USD 431 million. Among the EU4 countries and the UK, Germany had the largest market size at around USD 71 million, followed by France and the UK with approximately USD 46 million and USD 45 million, respectively.

*
In the EU4 countries and the UK, Germany had the highest number of chronic hand eczema cases, with nearly 493,000, followed by France and the UK with approximately 321,000 and 317,000 cases, respectively. In the US, nearly 1 million cases were diagnosed, and this number is projected to increase by 2034 due to environmental factors like weather conditions, and lifestyle factors such as stress and poor skincare habits.

*
Chronic hand eczema affects females more than males, primarily due to exposure to irritants from household and skincare products. In 2023, there were around 1 million females and 993,000 males with the condition in the US.

*
In the UK, cases of chronic hand eczema in 2023 were distributed across age groups as follows: approximately 52,000 cases in those aged 20-29 years, 98,000 in those aged 30-49 years, 29,000 in those aged 50-69 years, and 26,000 in those aged 70 and above.

*
In Japan, chronic hand eczema represented approximately 15% of global cases in 2023. Among various subtypes, irritant contact eczema was the most prevalent, accounting for around 27% of cases, while fingertip eczema had the lowest prevalence at about 4%. These cases are expected to increase by 2034, driven by modern lifestyle factors such as high stress, poor dietary habits, and sedentary behavior, which worsen inflammatory conditions like eczema in Japan.

*
Companies involved in chronic hand eczema treatment development, including Regeneron, Sanofi, Stiefel Laboratories, and Asana Biosciences, are exploring potential treatments that could be launched during the forecast period (2024-2034).

Strategise your business goals by understanding market dynamics @ Chronic Hand Eczema Market Landscape [https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Overview

Chronic hand eczema is a common inflammatory skin disorder that results in dry, red, itchy, and often painful patches on the hands. It can present as flare-ups followed by periods of remission or persist as a long-term condition. Various factors contribute to its development, including genetic predisposition, environmental triggers (such as irritants and allergens), frequent handwashing, and stress. The condition can significantly affect a person's quality of life, interfering with daily tasks and causing physical discomfort and emotional distress.

Diagnosing chronic hand eczema involves a detailed evaluation by a dermatologist or healthcare provider. This typically includes a review of the patient's medical history, a physical examination of the skin, and possibly additional tests. The doctor will assess the appearance and location of the skin lesions, inquire about symptoms like itching or pain, and discuss potential triggers such as occupation, hobbies, or personal care habits. In some cases, patch testing may be used to identify specific allergens. The healthcare provider may also rule out other conditions like contact dermatitis, psoriasis, or fungal infections through clinical examination or lab tests. The goal is to confirm the diagnosis and create a tailored treatment plan for effective management.

Do you know the treatment paradigms for different countries? Download our Chronic Hand Eczema Market Sample Report [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Epidemiology Segmentation

DelveInsight's Chronic Hand Eczema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Hand Eczema historical patient pools and forecasted Chronic Hand Eczema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Hand Eczema Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Chronic Hand Eczema Prevalence

*
Age-Specific Chronic Hand Eczema Prevalence

*
Gender-Specific Chronic Hand Eczema Prevalence

*
Diagnosed and Treatable Cases of Chronic Hand Eczema

Visit for more @ Chronic Hand Eczema Epidemiological Insights [https://www.delveinsight.com/report-store/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Hand Eczema Market Insights

Several drug classes are commonly used to treat chronic hand eczema. Topical corticosteroids are the primary treatment due to their anti-inflammatory effects, which help reduce itching, redness, and swelling during flare-ups. However, long-term use can lead to side effects like skin thinning, so they are usually prescribed for short durations or in combination with other treatments.

Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, are effective for sensitive areas like the face and hands, as they suppress the skin's immune response. Emollients and moisturizers are essential for managing the condition, as they help restore the skin barrier, prevent water loss, and soothe dry, irritated skin. These are often used alongside other treatments to maintain hydration and prevent flare-ups.

Additionally, topical immunomodulators like crisaborole help reduce inflammation and eczema symptoms by modulating the skin's immune response. They are typically used when corticosteroids or calcineurin inhibitors are ineffective or not tolerated.

Chronic Hand Eczema Market Outlook

Current treatments for chronic hand eczema mainly involve topical therapies, such as corticosteroids, calcineurin inhibitors, and emollients/moisturizers, aimed at relieving symptoms, reducing inflammation, and restoring the skin barrier. In more severe cases, systemic treatments like oral medications or biologics may be used. The market for chronic hand eczema treatments is evolving, influenced by factors such as advances in medical knowledge, the development of new therapies, changing patient preferences, greater awareness of eczema management among healthcare providers and patients, and environmental and lifestyle factors.

Chronic Hand Eczema Marketed Drugs

*
TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories

Chronic Hand Eczema Emerging Drugs

*
ARQ-252: Arcutis Biotherapeutics

*
Delgocitinib: LEO Pharma/Japan Tobacco

Chronic Hand Eczema Key Companies

*
LEO Pharma

*
Japan Tobacco

*
Asana Biosciences

*
And others

For more information, visit Chronic Hand Eczema Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Hand Eczema Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Hand Eczema, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Hand Eczema epidemiology in the 7MM

*
Chronic Hand Eczema marketed and emerging therapies

*
Chronic Hand Eczema companies

*
Chronic Hand Eczema market drivers and barriers

Table of Contents:

1 Chronic Hand Eczema Market Key Comprehensive Insights

2 Chronic Hand Eczema Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Hand Eczema

4 Chronic Hand Eczema Market Analysis Overview at a Glance

5 Executive Summary of Chronic Hand Eczema

6 Chronic Hand Eczema Epidemiology and Market Methodology

7 Chronic Hand Eczema Epidemiology and Patient Population

8 Chronic Hand Eczema Patient Journey

9 Chronic Hand Eczema Treatment Algorithm, Chronic Hand Eczema Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Hand Eczema Clinical Trials

11 Chronic Hand Eczema Marketed Therapies

12 Chronic Hand Eczema Emerging Therapies

13 Chronic Hand Eczema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Hand Eczema

16 Chronic Hand Eczema Market Key Opinion Leaders Reviews

18 Chronic Hand Eczema Market Drivers

19 Chronic Hand Eczema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Hand Eczema Epidemiology 2034

DelveInsight's "Chronic Hand Eczema - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Hand Eczema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hand Eczema Pipeline 2024

"Chronic Hand Eczema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Hand Eczema market. A detailed picture of the Chronic Hand Eczema pipeline landscape is provided, which includes the disease overview and Chronic Hand Eczema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-hand-eczema-market-expected-to-rise-2034-leo-pharma-japan-tobacco-asana-biosciences-expected-to-drive-market]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.